Kuros Biosciences receives US marketing clearance for intervertebral body fusion device

Schlieren (Zurich), Switzerland, March 13, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has received clearance for the Kuros TLIF cage from the U.S. Food and Drug Administration (FDA).
The TLIF cage has been developed for the use with KUR-113, Kuros’s advanced Fibrin-PTH product
candidate for spinal fusion. The combination of KUR-113 with the TLIF cage will be investigated in upcoming clinical trials.
The Kuros TLIF cage is intended for use in intervertebral body fusion of the spine. The cage comes in a
range of sizes and includes instruments to prepare the disc space and implant the device. The cage is
cleared for use in the lumbar spine (L1 to S1) in combination with autograft and/or allograft, under 510(k) number K183092.

Press release